These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35634965)

  • 1. Relapse prevention through health technology program reduces hospitalization in schizophrenia.
    Homan P; Schooler NR; Brunette MF; Rotondi A; Ben-Zeev D; Gottlieb JD; Mueser KT; Achtyes ED; Gingerich S; Marcy P; Meyer-Kalos P; Hauser M; John M; Robinson DG; Kane JM
    Psychol Med; 2023 Jul; 53(9):4114-4120. PubMed ID: 35634965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of Care.
    Brunette MF; Rotondi AJ; Ben-Zeev D; Gottlieb JD; Mueser KT; Robinson DG; Achtyes ED; Gingerich S; Marcy P; Schooler NR; Meyer-Kalos P; Kane JM
    Psychiatr Serv; 2016 Apr; 67(4):444-7. PubMed ID: 26725297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system.
    Spaniel F; Novak T; Bankovska Motlova L; Capkova J; Slovakova A; Trancik P; Matejka M; Höschl C
    J Psychiatr Ment Health Nurs; 2015 Dec; 22(10):811-20. PubMed ID: 26176646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.
    Gumley AI; Bradstreet S; Ainsworth J; Allan S; Alvarez-Jimenez M; Birchwood M; Briggs A; Bucci S; Cotton S; Engel L; French P; Lederman R; Lewis S; Machin M; MacLennan G; McLeod H; McMeekin N; Mihalopoulos C; Morton E; Norrie J; Reilly F; Schwannauer M; Singh SP; Sundram S; Thompson A; Williams C; Yung A; Aucott L; Farhall J; Gleeson J
    Health Technol Assess; 2022 May; 26(27):1-174. PubMed ID: 35639493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.
    Marshall M; Crowther R; Almaraz-Serrano A; Creed F; Sledge W; Kluiter H; Roberts C; Hill E; Wiersma D; Bond GR; Huxley P; Tyrer P
    Health Technol Assess; 2001; 5(21):1-75. PubMed ID: 11532238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
    Beasley CM; Sutton VK; Hamilton SH; Walker DJ; Dossenbach M; Taylor CC; Alaka KJ; Bykowski D; Tollefson GD;
    J Clin Psychopharmacol; 2003 Dec; 23(6):582-94. PubMed ID: 14624189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A program for relapse prevention in schizophrenia: a controlled study.
    Herz MI; Lamberti JS; Mintz J; Scott R; O'Dell SP; McCartan L; Nix G
    Arch Gen Psychiatry; 2000 Mar; 57(3):277-83. PubMed ID: 10711914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2018; 18(5):1-141. PubMed ID: 30443277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prodromal symptoms in schizophrenic relapse: A descriptive and comparative study].
    Bouhlel S; Jones Y; Khelifa E; Msolly M; Melki W; El-Hechmi Z
    Encephale; 2012 Oct; 38(5):397-403. PubMed ID: 23062453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial.
    Komatsu H; Sekine Y; Okamura N; Kanahara N; Okita K; Matsubara S; Hirata T; Komiyama T; Watanabe H; Minabe Y; Iyo M
    Schizophr Res; 2013 Oct; 150(1):240-4. PubMed ID: 23998952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of Texting 4 Relapse Prevention, Text Messaging-Based Relapse Prevention Program for People With Schizophrenia and Schizoaffective Disorder.
    Ybarra ML; Rodriguez KM; Fehmie DA; Mojtabai R; Cullen B
    J Nerv Ment Dis; 2022 Feb; 210(2):123-128. PubMed ID: 34570061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing Texting for Relapse Prevention: A Scalable mHealth Program for People With Schizophrenia and Schizoaffective Disorder.
    Ybarra ML; Rodriguez K; Madison H; Mojtabai R; Cullen BA
    J Nerv Ment Dis; 2019 Oct; 207(10):854-862. PubMed ID: 31503175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of rehospitalization in schizophrenia: results of an integrated care project in Germany.
    Schmidt-Kraepelin C; Janssen B; Gaebel W
    Eur Arch Psychiatry Clin Neurosci; 2009 Nov; 259 Suppl 2():S205-12. PubMed ID: 19876680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
    Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
    BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study.
    Cullen BA; Rodriguez K; Eaton WW; Mojtabai R; Von Mach T; Ybarra ML
    Psychiatry Res; 2020 Oct; 292():113346. PubMed ID: 32750572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of information technology assisted relapse prevention program on relapse among people who live with severe mental disorders.
    Ehsani M; Maarefvand M; Hosseinzadeh S; Zabihi Poursaadati M
    Int J Soc Psychiatry; 2024 May; 70(3):531-541. PubMed ID: 38166425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson D; Woerner MG; Alvir JM; Bilder R; Goldman R; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Lieberman JA
    Arch Gen Psychiatry; 1999 Mar; 56(3):241-7. PubMed ID: 10078501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.
    Bighelli I; Rodolico A; García-Mieres H; Pitschel-Walz G; Hansen WP; Schneider-Thoma J; Siafis S; Wu H; Wang D; Salanti G; Furukawa TA; Barbui C; Leucht S
    Lancet Psychiatry; 2021 Nov; 8(11):969-980. PubMed ID: 34653393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.